Efficacy and safety of a novel κ-agonist for managing intractable pruritus in dialysis patients

Hiroo Kumagai, Toshiya Ebata, Kenji Takamori, Katsumasa Miyasato, Taro Muramatsu, Hidetomo Nakamoto, Masanao Kurihara, Tomoji Yanagita, Hiromichi Suzuki

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Background: Our previous placebo-controlled, prospective, double-blind study demonstrated that a new opioid κ-receptor agonist, nalfurafine hydrochloride, effectively reduced treatment-resistant pruritus in 337 hemodialysis patients. Thus, we designed this study to evaluate prospectively the efficacy, safety, addiction liability, and pharmacokinetics of nalfurafine given orally for 1 year. Methods: This open-label study examined the effects and adverse drug reactions (ADRs) of 52-week oral administration of nalfurafine hydrochloride (5 μg/day) in 211 hemodialysis patients with a treatment-resistant itch. Results: Of 211 patients, 145 completed the study as scheduled. The mean pruritus value assessed by the visual analogue scale was 75.2 mm during the pre-observation period, which decreased significantly to 50.9 and 30.9 mm in week 2 and 52, respectively, indicating a long-lasting efficacy. ADRs occurred in 103 patients (48.8%). Frequent ADRs were insomnia (sleep disturbance, 19.4%), constipation (7.1%) and increased blood prolactin (3.3%), similar to previous reports. Regarding addiction liability, it appeared unlikely that nalfurafine hydrochloride was abused. After the start of treatment, plasma drug levels reached a steady state in week 2 with no apparent tendency of systemic accumulation. Conclusions: Nalfurafine hydrochloride, orally administered at 5 μg/day for 52 weeks to hemodialysis patients, produced a long-term suppression of pruritus without significant safety problems.

Original languageEnglish
Pages (from-to)175-183
Number of pages9
JournalAmerican Journal of Nephrology
Volume36
Issue number2
DOIs
Publication statusPublished - 2012 Aug

Fingerprint

Pruritus
Dialysis
Safety
Drug-Related Side Effects and Adverse Reactions
Renal Dialysis
Sleep Initiation and Maintenance Disorders
Opioid Receptors
Constipation
Visual Analog Scale
Double-Blind Method
Prolactin
Oral Administration
Sleep
Therapeutics
Pharmacokinetics
Placebos
Observation
TRK 820
Pharmaceutical Preparations

Keywords

  • κ-Receptor agonist
  • Hemodialysis
  • Long-term efficacy and safety
  • Nalfurafine hydrochloride
  • Pruritus

ASJC Scopus subject areas

  • Nephrology

Cite this

Efficacy and safety of a novel κ-agonist for managing intractable pruritus in dialysis patients. / Kumagai, Hiroo; Ebata, Toshiya; Takamori, Kenji; Miyasato, Katsumasa; Muramatsu, Taro; Nakamoto, Hidetomo; Kurihara, Masanao; Yanagita, Tomoji; Suzuki, Hiromichi.

In: American Journal of Nephrology, Vol. 36, No. 2, 08.2012, p. 175-183.

Research output: Contribution to journalArticle

Kumagai, H, Ebata, T, Takamori, K, Miyasato, K, Muramatsu, T, Nakamoto, H, Kurihara, M, Yanagita, T & Suzuki, H 2012, 'Efficacy and safety of a novel κ-agonist for managing intractable pruritus in dialysis patients', American Journal of Nephrology, vol. 36, no. 2, pp. 175-183. https://doi.org/10.1159/000341268
Kumagai, Hiroo ; Ebata, Toshiya ; Takamori, Kenji ; Miyasato, Katsumasa ; Muramatsu, Taro ; Nakamoto, Hidetomo ; Kurihara, Masanao ; Yanagita, Tomoji ; Suzuki, Hiromichi. / Efficacy and safety of a novel κ-agonist for managing intractable pruritus in dialysis patients. In: American Journal of Nephrology. 2012 ; Vol. 36, No. 2. pp. 175-183.
@article{ee4c1108b1db49b5abced95a0a9967c9,
title = "Efficacy and safety of a novel κ-agonist for managing intractable pruritus in dialysis patients",
abstract = "Background: Our previous placebo-controlled, prospective, double-blind study demonstrated that a new opioid κ-receptor agonist, nalfurafine hydrochloride, effectively reduced treatment-resistant pruritus in 337 hemodialysis patients. Thus, we designed this study to evaluate prospectively the efficacy, safety, addiction liability, and pharmacokinetics of nalfurafine given orally for 1 year. Methods: This open-label study examined the effects and adverse drug reactions (ADRs) of 52-week oral administration of nalfurafine hydrochloride (5 μg/day) in 211 hemodialysis patients with a treatment-resistant itch. Results: Of 211 patients, 145 completed the study as scheduled. The mean pruritus value assessed by the visual analogue scale was 75.2 mm during the pre-observation period, which decreased significantly to 50.9 and 30.9 mm in week 2 and 52, respectively, indicating a long-lasting efficacy. ADRs occurred in 103 patients (48.8{\%}). Frequent ADRs were insomnia (sleep disturbance, 19.4{\%}), constipation (7.1{\%}) and increased blood prolactin (3.3{\%}), similar to previous reports. Regarding addiction liability, it appeared unlikely that nalfurafine hydrochloride was abused. After the start of treatment, plasma drug levels reached a steady state in week 2 with no apparent tendency of systemic accumulation. Conclusions: Nalfurafine hydrochloride, orally administered at 5 μg/day for 52 weeks to hemodialysis patients, produced a long-term suppression of pruritus without significant safety problems.",
keywords = "κ-Receptor agonist, Hemodialysis, Long-term efficacy and safety, Nalfurafine hydrochloride, Pruritus",
author = "Hiroo Kumagai and Toshiya Ebata and Kenji Takamori and Katsumasa Miyasato and Taro Muramatsu and Hidetomo Nakamoto and Masanao Kurihara and Tomoji Yanagita and Hiromichi Suzuki",
year = "2012",
month = "8",
doi = "10.1159/000341268",
language = "English",
volume = "36",
pages = "175--183",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of a novel κ-agonist for managing intractable pruritus in dialysis patients

AU - Kumagai, Hiroo

AU - Ebata, Toshiya

AU - Takamori, Kenji

AU - Miyasato, Katsumasa

AU - Muramatsu, Taro

AU - Nakamoto, Hidetomo

AU - Kurihara, Masanao

AU - Yanagita, Tomoji

AU - Suzuki, Hiromichi

PY - 2012/8

Y1 - 2012/8

N2 - Background: Our previous placebo-controlled, prospective, double-blind study demonstrated that a new opioid κ-receptor agonist, nalfurafine hydrochloride, effectively reduced treatment-resistant pruritus in 337 hemodialysis patients. Thus, we designed this study to evaluate prospectively the efficacy, safety, addiction liability, and pharmacokinetics of nalfurafine given orally for 1 year. Methods: This open-label study examined the effects and adverse drug reactions (ADRs) of 52-week oral administration of nalfurafine hydrochloride (5 μg/day) in 211 hemodialysis patients with a treatment-resistant itch. Results: Of 211 patients, 145 completed the study as scheduled. The mean pruritus value assessed by the visual analogue scale was 75.2 mm during the pre-observation period, which decreased significantly to 50.9 and 30.9 mm in week 2 and 52, respectively, indicating a long-lasting efficacy. ADRs occurred in 103 patients (48.8%). Frequent ADRs were insomnia (sleep disturbance, 19.4%), constipation (7.1%) and increased blood prolactin (3.3%), similar to previous reports. Regarding addiction liability, it appeared unlikely that nalfurafine hydrochloride was abused. After the start of treatment, plasma drug levels reached a steady state in week 2 with no apparent tendency of systemic accumulation. Conclusions: Nalfurafine hydrochloride, orally administered at 5 μg/day for 52 weeks to hemodialysis patients, produced a long-term suppression of pruritus without significant safety problems.

AB - Background: Our previous placebo-controlled, prospective, double-blind study demonstrated that a new opioid κ-receptor agonist, nalfurafine hydrochloride, effectively reduced treatment-resistant pruritus in 337 hemodialysis patients. Thus, we designed this study to evaluate prospectively the efficacy, safety, addiction liability, and pharmacokinetics of nalfurafine given orally for 1 year. Methods: This open-label study examined the effects and adverse drug reactions (ADRs) of 52-week oral administration of nalfurafine hydrochloride (5 μg/day) in 211 hemodialysis patients with a treatment-resistant itch. Results: Of 211 patients, 145 completed the study as scheduled. The mean pruritus value assessed by the visual analogue scale was 75.2 mm during the pre-observation period, which decreased significantly to 50.9 and 30.9 mm in week 2 and 52, respectively, indicating a long-lasting efficacy. ADRs occurred in 103 patients (48.8%). Frequent ADRs were insomnia (sleep disturbance, 19.4%), constipation (7.1%) and increased blood prolactin (3.3%), similar to previous reports. Regarding addiction liability, it appeared unlikely that nalfurafine hydrochloride was abused. After the start of treatment, plasma drug levels reached a steady state in week 2 with no apparent tendency of systemic accumulation. Conclusions: Nalfurafine hydrochloride, orally administered at 5 μg/day for 52 weeks to hemodialysis patients, produced a long-term suppression of pruritus without significant safety problems.

KW - κ-Receptor agonist

KW - Hemodialysis

KW - Long-term efficacy and safety

KW - Nalfurafine hydrochloride

KW - Pruritus

UR - http://www.scopus.com/inward/record.url?scp=84864527257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864527257&partnerID=8YFLogxK

U2 - 10.1159/000341268

DO - 10.1159/000341268

M3 - Article

C2 - 22868684

AN - SCOPUS:84864527257

VL - 36

SP - 175

EP - 183

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 2

ER -